Chemotherapy of malaria.
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005493:Folic Acid Antagonists; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D010616:Phenanthrenes / Q000627:therapeutic use; D010961:Plasmodium; D010963:Plasmodium falciparum; D010965:Plasmodium malariae; D010966:Plasmodium vivax; D011739:Pyrimethamine / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D013444:Sulfisoxazole / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D000962:Antimalarials; D005493:Folic Acid Antagonists; D010616:Phenanthrenes; D011804:Quinolines; D013449:Sulfonamides; D013450:Sulfones; D013411:Sulfadiazine; D013444:Sulfisoxazole; D011803:Quinine; D013752:Tetracycline; D011739:Pyrimethamine